Comparative Pharmacology
Head-to-head clinical analysis: FLUOCET versus POKONZA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUOCET versus POKONZA.
FLUOCET vs POKONZA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by blocking the reuptake of serotonin into presynaptic neurons.
POKONZA (ponazuril) is a triazine antiprotozoal agent that inhibits the mitochondrial electron transport chain at the cytochrome bc1 complex, disrupting the parasite's energy metabolism and leading to its death. It is active against apicomplexan parasites such as Toxoplasma gondii, Neospora caninum, and Sarcocystis neurona.
20 mg orally once daily in the morning.
Intravenous: 0.1 mg/kg every 8 hours for 28 consecutive days per 6-week cycle.
None Documented
None Documented
Fluoxetine: 4-6 days (single dose), 4-6 days (chronic); Norfluoxetine: 16 days. Clinical context: Steady state achieved after 4-5 weeks; extended half-life reduces withdrawal risk but prolongs washout.
Terminal elimination half-life 12-15 hours; clinically significant for once-daily dosing with steady-state achieved in 3-5 days
Renal: 80% as fluoxetine and its metabolites (60% as glucuronide conjugates, 20% as parent and norfluoxetine). Fecal: 15% (biliary).
Primarily renal excretion (70-80% unchanged drug); biliary/fecal elimination accounts for 15-20%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid